World Markets Ophthalmology
- How are pharmaceutical companies and regulatory bodies dealing with the increasing costs of—and market access barriers to—new ophthalmology drugs?
- Which disease area within ophthalmology has the highest growth opportunity?
- How are off-patent drugs performing in terms of pricing in different countries?
IHS Global Insight's World Markets Ophthalmology service is a comprehensive online tool designed to answer precisely these kinds of questions.
The service details the full value proposition of any ophthalmology product (whether in early development or fully marketed) and links the price, cost, and specific reimbursement guidelines of new medicines with the clinical data that underpin them.
This service enables you to instantly:
- Understand how approvals and reimbursement were secured—or not secured—based on clinical endpoints, design, and results, as well as pricing
- Compare and break down the cost of drugs per day of treatment in each of the major disease areas
- Understand the key market access barriers to new ophthalmology drugs, including clinical guidelines, special authority restrictions, and detailed overviews of cost-effectiveness calculations and reimbursement decisions
- Find new licensing opportunities and key areas of research and development
- Assess the risk posed by drugs under development based on disease, drug class, and manufacturer
This service is ideally suited to:
- Strategic planners
- Pricing managers
- Business development managers
- Competitive intelligence managers
- Research associates
- Regulatory executives
SERVICE FEATURES
The Ophtha-Online Database:
Coverage of over 500 drugs, both approved and under development, for 12 diseases in the
ophthalmology market, including:
- Glaucoma
- Intraocular Pressure and Ocular Hypertension
- Macular Degeneration
- Diabetic Macular Edema
- Conjunctivitis (bacterial, allergic, and all other forms)
- Eye Infections (bacterial, viral, and fungal)
- Dry Eyes
- Uveitis
- Retinal Vessel Occlusion
- Ocular Surface Disease
- Retinitis Pigmentosa
- Fungal Keratitis
The database also includes global pipelines and pricing, reimbursement, approval, and cost information for medicines in France, Germany, Italy, Japan, Spain, the United Kingdom,
and the United States.
Up to 55 sets of data per drug, from Phase I through approval, including:
- Pricing and Reimbursement: average cost per drug per day in each of the disease areas for any marketed drug, taking into account the price, dosing, average duration of use, and presentation; provides ex-manufacturing prices, reimbursement restrictions, and guidelines; also provides analysis of the average level of cost outside the reimbursement structure
- Research and Development: clinical trial design, endpoints, results, and forward-looking approval information
- Disease Area: drug classes, product concentration in each drug class, and disease landscape
- Corporate: licensing, patent, and strategic-planning information
Same-Day Analysis and Profiles:
- Same-Day Analysis of all key news and events related to the ophthalmology market. This is supplemented with a monthly Ophthalmology Milestones Bulletin, which summarizes updates to the database and provides editorial analysis.
|
